摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-Butoxycarbonylamino-acetic acid (S)-11-(tert-butyl-dimethyl-silanyl)-4-ethyl-9-methoxymethoxy-3,13-dioxo-3,4,12,13-tetrahydro-1H-2-oxa-6,12a-diaza-dibenzo[b,h]fluoren-4-yl ester | 905843-14-3

中文名称
——
中文别名
——
英文名称
tert-Butoxycarbonylamino-acetic acid (S)-11-(tert-butyl-dimethyl-silanyl)-4-ethyl-9-methoxymethoxy-3,13-dioxo-3,4,12,13-tetrahydro-1H-2-oxa-6,12a-diaza-dibenzo[b,h]fluoren-4-yl ester
英文别名
[(19S)-10-[tert-butyl(dimethyl)silyl]-19-ethyl-7-(methoxymethoxy)-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl] 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetate
tert-Butoxycarbonylamino-acetic acid (S)-11-(tert-butyl-dimethyl-silanyl)-4-ethyl-9-methoxymethoxy-3,13-dioxo-3,4,12,13-tetrahydro-1H-2-oxa-6,12a-diaza-dibenzo[b,h]fluoren-4-yl ester化学式
CAS
905843-14-3
化学式
C35H45N3O9Si
mdl
——
分子量
679.843
InChiKey
CQIIDBHEXFCPPF-DHUJRADRSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.85
  • 重原子数:
    48
  • 可旋转键数:
    12
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.51
  • 拓扑面积:
    143
  • 氢给体数:
    1
  • 氢受体数:
    10

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    tert-Butoxycarbonylamino-acetic acid (S)-11-(tert-butyl-dimethyl-silanyl)-4-ethyl-9-methoxymethoxy-3,13-dioxo-3,4,12,13-tetrahydro-1H-2-oxa-6,12a-diaza-dibenzo[b,h]fluoren-4-yl ester三氟乙酸二氯甲烷 为溶剂, 以62%的产率得到Amino-acetic acid (S)-11-(tert-butyl-dimethyl-silanyl)-4-ethyl-9-hydroxy-3,13-dioxo-3,4,12,13-tetrahydro-1H-2-oxa-6,12a-diaza-dibenzo[b,h]fluoren-4-yl ester; compound with trifluoro-acetic acid
    参考文献:
    名称:
    喜树碱的α-氨基酸酯前药活化的动力学和机理。
    摘要:
    NMR光谱法和定量动力学分析表明,抗肿瘤剂喜树碱的α-氨基酸酯前药和更有效的亲脂性硅酸盐酯类似物DB-67可通过非酶机制进行定量转化为其药理活性内酯。 pH 7.4优于直接水解。替代途径涉及在喜树碱E-环羰基上可逆的分子内亲核胺攻击,以生成内酰胺(I),然后进行第二次分子内反应,以生成双环半原酸酯(I')。分离出中间体,并使用NMR光谱法显示其在DMSO中以半原酸酯为主导的明显平衡存在。在37°C下于水性缓冲液(pH 3.0和7.4)中监测喜树碱或含有α-NH(2)或α-NHCH(3)及其相应半甲酸酯的DB-67前药的转化率与时间的关系,动力学数据适合基于所提出机制的模型。结果表明,虽然前药在pH 3时相对稳定,但在生理条件下(pH 7.4),前药及其相应的半甲酸酯中间体都容易释放内酯。发现在体外使用人乳腺癌细胞系(MDA-MB-435S),甘氨酸酯及其半原酸酯比N-甲基甘氨酸或其相应的半
    DOI:
    10.1021/jm060016l
  • 作为产物:
    参考文献:
    名称:
    A Versatile Prodrug Approach for Liposomal Core-Loading of Water-Insoluble Camptothecin Anticancer Drugs
    摘要:
    We describe a versatile prodrug strategy for loading the liposomal lumen with water-insoluble camptothecins. The procedure involves conversion of an active camptothecin analogue to a 20-OR omega-aminoalkanoanic ester prodrug in which R = CO[CH(2)](n)()NH(2) and n = 1-3. The basic amino group of the prodrug serves three roles. First, at pH ranges of 3-5, the amine enhances aqueous solubility. Second, it enhances responsiveness to a transmembrane ammonium sulfate gradient across the liposomal bilayer, thereby facilitating active loading of the agent into the liposomal aqueous core. Third, at a physiological pH of 7 or above (the pH to be encountered following drug release at the tumor site), the nucleophilicity of the amine manifests itself and cyclization to the C-21 carbonyl carbon occurs. This cyclization triggers a rapid and convenient nonenzymatic decomposition process that releases active camptothecin. Accordingly, this novel liposomal approach offers a potential system for tumor-targeting prodrugs of many water-insoluble camptothecins, including the highly lipophilic and clinically attractive analogues SN-38, 9-nitrocamptothecin and DB-67. The rate of formation of the active agent at the tumor site can be controlled through the selection of n (the length of the alkyl spacer group).
    DOI:
    10.1021/ja0256212
点击查看最新优质反应信息

文献信息

  • Kinetics and Mechanisms of Activation of α-Amino Acid Ester Prodrugs of Camptothecins
    作者:Lin Song、Robert Bevins、Bradley D. Anderson
    DOI:10.1021/jm060016l
    日期:2006.7.1
    quantitative conversion to their pharmacologically active lactones via a nonenzymatic mechanism that at pH 7.4 is favored over direct hydrolysis. The alternate pathway involves the reversible intramolecular nucleophilic amine attack at the camptothecin E-ring carbonyl to generate a lactam (I) followed by a second intramolecular reaction to produce a bicyclic hemiortho ester (I'). The intermediates were isolated
    NMR光谱法和定量动力学分析表明,抗肿瘤剂喜树碱的α-氨基酸酯前药和更有效的亲脂性硅酸盐酯类似物DB-67可通过非酶机制进行定量转化为其药理活性内酯。 pH 7.4优于直接水解。替代途径涉及在喜树碱E-环羰基上可逆的分子内亲核胺攻击,以生成内酰胺(I),然后进行第二次分子内反应,以生成双环半原酸酯(I')。分离出中间体,并使用NMR光谱法显示其在DMSO中以半原酸酯为主导的明显平衡存在。在37°C下于水性缓冲液(pH 3.0和7.4)中监测喜树碱或含有α-NH(2)或α-NHCH(3)及其相应半甲酸酯的DB-67前药的转化率与时间的关系,动力学数据适合基于所提出机制的模型。结果表明,虽然前药在pH 3时相对稳定,但在生理条件下(pH 7.4),前药及其相应的半甲酸酯中间体都容易释放内酯。发现在体外使用人乳腺癌细胞系(MDA-MB-435S),甘氨酸酯及其半原酸酯比N-甲基甘氨酸或其相应的半
  • A Versatile Prodrug Approach for Liposomal Core-Loading of Water-Insoluble Camptothecin Anticancer Drugs
    作者:Xinli Liu、Bert C. Lynn、Junhong Zhang、Lin Song、David Bom、Wu Du、Dennis P. Curran、Thomas G. Burke
    DOI:10.1021/ja0256212
    日期:2002.7.1
    We describe a versatile prodrug strategy for loading the liposomal lumen with water-insoluble camptothecins. The procedure involves conversion of an active camptothecin analogue to a 20-OR omega-aminoalkanoanic ester prodrug in which R = CO[CH(2)](n)()NH(2) and n = 1-3. The basic amino group of the prodrug serves three roles. First, at pH ranges of 3-5, the amine enhances aqueous solubility. Second, it enhances responsiveness to a transmembrane ammonium sulfate gradient across the liposomal bilayer, thereby facilitating active loading of the agent into the liposomal aqueous core. Third, at a physiological pH of 7 or above (the pH to be encountered following drug release at the tumor site), the nucleophilicity of the amine manifests itself and cyclization to the C-21 carbonyl carbon occurs. This cyclization triggers a rapid and convenient nonenzymatic decomposition process that releases active camptothecin. Accordingly, this novel liposomal approach offers a potential system for tumor-targeting prodrugs of many water-insoluble camptothecins, including the highly lipophilic and clinically attractive analogues SN-38, 9-nitrocamptothecin and DB-67. The rate of formation of the active agent at the tumor site can be controlled through the selection of n (the length of the alkyl spacer group).
查看更多

同类化合物

鲁比替康 羧基喜树碱 盐酸拓扑替康 盐酸希明替康 盐酸伊立替康 拓扑替康-d6羧酸钠盐 拓扑替康-d5 拓扑替康 托泊替康醋酸盐; 醋酸拓扑替康; 4-乙基-4,9-二羟基-10-[(二甲基氨基)甲基]-1H-吡喃并[3',4':6,7]中氮茚并[1,2-b]喹啉-3,14(4H,12H)-二酮醋酸盐 戈维替康-沙西妥珠单抗 戈维替康-拉贝妥珠单抗 喜树碱钠盐 喜树碱杂质16 喜树碱 吉马替康 勒托替康 依喜替康甲磺酸盐 依喜替康 伊立替康杂质3 伊立替康 他克莫司 SN-38三-O-乙酰基-beta-D-葡萄糖醛酸甲酯 O-乙酰基喜树碱 N-去甲拓扑替康 N-去甲基拓扑替康-d3 9-羟基甲基-10-羟基喜树碱 9-硝基喜树碱 9-硝基-(20RS)-喜树碱 9-甲氧基喜树碱 9-甲氧基喜树碱 9-氮-10-羟基喜树碱 9-氨基喜树碱 8-乙基伊立替康 7-甲氧基甲基喜树碱 7-甲氧基喜树碱 7-甲基喜树碱 7-甲基-10-溴乙酰氨基甲基喜树碱 7-乙氧基甲基喜树碱 7-乙基喜树碱1-氧化物 7-乙基喜树碱 7-乙基-10-羟基喜树碱-D3 7-乙基-10-羟基喜树碱 7-乙基-10-(4-N-氨基戊酸)-1-哌啶)羰基氧基喜树碱盐酸盐 7,11-二乙基-10-羟基喜树碱 5-{[1-({[(4S)-4,11-二乙基-4-羟基-3,14-二氧代-3,4,12,14-四氢-1H-吡喃并[3',4':6,7]吲哚嗪并[1,2-b]喹啉-9-基]氧基}羰基)-4-哌啶基]氨基}戊酸 4-乙基-4-羟基-3,4,12,14-四氢-1H-吡喃并[3'4':6,7]吲哚嗪并[1,2-b]喹啉-3,14-二酮 4,11-二乙基-4,9-二羟基-1H-吡喃并[3’,4’:6,7]中氮茚并[1,2-B]喹啉-3,14(4H,12H)-二酮 4,11-二乙基-4,9-二羟基-1H-吡喃并[3',4':6,7]吲哚嗪并[1,2-b]喹啉-3,14(4H,12H)-二酮 20R-喜树碱 2-(氨甲基)苯乙酸盐酸盐